Document Detail


Effects of ammonia solution on the gastric mucosa in cirrhotic rats and therapeutic effects of geranylgeranylacetone.
MedLine Citation:
PMID:  10385060     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: We designed an animal model in order to clarify whether Helicobacter pylori infection causes the gastric mucosal lesion frequently seen in cirrhotic patients. METHODS: Ammonia (NH3) solution was given to rats with carbon tetrachloride-induced cirrhosis. The gastric mucosal hexosamine (Hx) content and histopathological findings in the cirrhotic rats were analysed and compared with those of the intact liver rats. Moreover, the usefulness of geranylgeranylacetone (GGA) was investigated in both rat groups. Both rat groups were subdivided according to the treatment as follows: a control group, an NH3 (0.02% solution) group, and an NH3 + GGA (400 mg/kg per day) group; and fed for 4 weeks. RESULTS: The gastric mucosal Hx content of the control group of the cirrhotic rats (16.7 +/- 5.2 microg/mg) was significantly lower than that of the control group of the intact liver rats (26.6 +/- 4.5 microg/mg, P < 0.05). In the cirrhotic rats, the Hx content of both the NH3 (31.9 +/- 13.1 microg/mg) and the NH3 + GGA group (31.9 +/- 9.8 microg/mg) was significantly higher than the Hx content of the control group (P < 0.05). Microscopically, in the cirrhotic rats, while scattered mucosal erosions were recognized in three of five rats of the NH3 group, there were no erosions in any rats of the NH3 + GGA group. CONCLUSIONS: These data suggest that the gastric mucosal defence mechanism is defective in liver cirrhosis and that NH3 enhances this defensive mechanism by acting as mild irritant; however, in some cirrhotics this results in gastric erosion due to excessive irritation. Geranylgeranylacetone protects the gastric mucosa against NH3 irritation in cirrhotics without enhancing the Hx content. Thus, H. pylori infection may be a possible cause of the gastric mucosal lesion in patients with liver cirrhosis. The mechanism of the therapeutic effect of GGA is not due to an enhancement of the gastric mucosal Hx content.
Authors:
M Sugimoto; Y Machida; K Ito
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of gastroenterology and hepatology     Volume:  14     ISSN:  0815-9319     ISO Abbreviation:  J. Gastroenterol. Hepatol.     Publication Date:  1999 Jun 
Date Detail:
Created Date:  1999-09-08     Completed Date:  1999-09-08     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  8607909     Medline TA:  J Gastroenterol Hepatol     Country:  AUSTRALIA    
Other Details:
Languages:  eng     Pagination:  529-33     Citation Subset:  IM    
Affiliation:
Second Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan. motonobu@bd.mbn.or.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Ammonia / pharmacology*
Animals
Anti-Ulcer Agents / therapeutic use*
Carbon Tetrachloride
Disease Models, Animal
Diterpenes / therapeutic use*
Gastric Mucosa / drug effects*,  metabolism,  pathology
Hexosamines / metabolism
Liver Cirrhosis, Experimental / chemically induced,  complications*,  pathology
Male
Rats
Rats, Sprague-Dawley
Stomach Ulcer / complications,  prevention & control*
Chemical
Reg. No./Substance:
0/Anti-Ulcer Agents; 0/Diterpenes; 0/Hexosamines; 56-23-5/Carbon Tetrachloride; 6809-52-5/geranylgeranylacetone; 7664-41-7/Ammonia

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of anti-Helicobacter pylori treatment in H. pylori-positive and cytoprotective drugs in H. pylo...
Next Document:  Case report: A case of lymphoepithelioma-like carcinoma of the oesophagus and review of the literatu...